Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524816 | NSE Symbol : NATCOPHARM | ISIN : INE987B01026 | Industry : Pharmaceuticals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
28-Oct-2024	12-Nov-2024	Quarterly Results	Quarterly Results & Interim Dividend Outcome of Board Meeting Declared second interim dividend of Rs.1.50 (Rupees one and fifty paise only) (75%) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2024-25. The date for taking on record of its shareholders eligible for the purpose of payment ofsecond interim dividend i.e., record date is fixed as Monday, the 25th day of November 2024. The payment of said interim dividend will start from 2nd December 2024. (As Per BSE Announcement Dated on 12.11.2024)
26-Jul-2024	12-Aug-2024	Quarterly Results	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve the Un-audited Financial Results for the quarter ended June 30 2024 and declaration of Interim Dividend for FY 2024-25 if any Unaudited Financial Results for the quarter ended 30th June 2024 along with Limited Review Report (As Per BSE Announcement Dated on 12.08.2024)
09-May-2024	27-May-2024	Accounts	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve the Audited Financial Results for the quarter and year ended March 31 2024 Audited Financial Results for the quarter and year ended 31st March, 2024 (As Per BSE Announcement Dated on 27.05.2024)
02-Feb-2024	14-Feb-2024	Interim Dividend	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve Consider the Unaudited Results for the quarter and nine months ended 31st December 2023 and Interim Dividend for the Financial year 2023-24 if any outcome of Board Meeting Unaudited Financial Results for the quarter and nine months ended 31st December, 2023 (As Per BSE Announcement Dated 14.02.2024)
03-Nov-2023	14-Nov-2023	Quarterly Results	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve The Unaudited Financial Results for the quarter and half year ended 30th September 2023 and declaration of second interim dividend if any Outcome of the Board Meeting Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September 2023 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ('Listing Regulations') along with Limited Review Report of the Statutory Auditors. Please find enclosed herewith a copy of the same for your information. Outcome of the Board Meeting (As per BSE Announcement Dated on 14/11/2023) Declared second interim dividend of Rs.1.25 (Rupees one and twenty five paise only) (62.50 %) each per equity share of Rs.2/- (Rupees two only) each for the financial year 2023-24. The date for taking on record of its shareholders eligible for the purpose of payment ofsecond interim dividend i.e.,record date is fixed as Friday, the 24th day of November 2023. The payment of said interim dividend will start from 1st December 2023. (As Per BSE Announcement Dated on 15.11.2023)
31-Jul-2023	09-Aug-2023	Quarterly Results	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 inter alia to consider and approve Unaudited Financial Results for the quarter ended 30th June 2023 and to consider interim dividend for the Financial Year 2023-24 if any. Board approved:- 1. Declared interim dividend of Rs.7/- (Rupees Seven only) (350 %) per equity share of Rs.2/- (Rupees two only) each for the financial year 2023-24. The date for taking on record of its shareholders eligible for the purpose of payment of interim dividend i.e., record date is fixed as Tuesday, the 22nd day of August 2023. The payment of said interim dividend will start from 30th August 2023. 2. Notice of the 40th Annual General Meeting and the Board had authorised Sri V.C. Nannapaneni, Managing Director for finalizing the date, time, book closure dates and mode of conducting of Annual General Meeting for the financial year 2022-23. 3. Amendment of Materiality Policy of the Company i.e., NATCO's Policy for determination of Materiality of an Event or Information and copy of the policy will be made available on the website of the Company. 4. Incorporate a Subsidiary Company in United Kingdom with an investment up to an amount not exceeding USD 3,000,000 (United State Dollar Three Million only). Unaudited Financial Results for the quarter ended 30th June, 2023 Outcome of Board Meeting (As Per BSE Announcement Dated on 09.08.2023)
19-May-2023	29-May-2023	Accounts	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve the Audited Financial Results for the quarter and year ended 31st March 2023 Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2023 (As Per BSE Announcement dated on 29.05.2023)
20-Apr-2023	20-Apr-2023	Subsidiary Company	The Board of Directors have approved to incorporate a Subsidiary Company in Indonesia with an investment up to an amount not exceeding US$ 3 Million (Three Million United States Dollars only), of which, initially the Company will invest US$ 1 Million (One Million United States Dollars only) for a stake of 51% (Fifty One Percent) as capital contribution and balance will be invested by the Company as and when the funds are required by the subsidiary Company. The balance stake of 49% (Forty Nine Percent) will be held by PT. Mitra Medis Exim (MME), that belongs to Mitra Jaya Group which is a 40 year old multi-diversified group, as the co-promoter of the proposed subsidiary Company. MME is in the business of distribution for active pharmaceutical ingredients and excipients for the end users in Indonesia. The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid acquisition is enclosed as Annexure - I The Board of Directors have approved to incorporate a Subsidiary Company in Indonesia with an investment up to an amount not exceeding US$ 3 Million (Three Million United States Dollars only), of which, initially the Company will invest US$ 1 Million (One Million United States Dollars only) for a stake of 51% (Fifty One Percent) as capital contribution and balance will be invested by the Company as and when the funds are required by the subsidiary Company. The balance stake of 49% (Forty Nine Percent) will be held by PT. Mitra Medis Exim (MME), that belongs to Mitra Jaya Group which is a 40 year old multi-diversified group, as the co-promoter of the proposed subsidiary Company. MME is in the business of distribution for active pharmaceutical ingredients and excipients for the end users in Indonesia.
02-Mar-2023	08-Mar-2023	Buy Back	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/03/2023 inter alia to consider and approve proposal for buyback of fully paid up equity shares of the Company The Board of Directors approved the Buy Back of Equity Shares of the Company (As Per BSE Announcement Dated on 08.03.2023) The Board of Directors have approved to incorporate a Subsidiary Company in Indonesia with an investment up to an amount not exceeding US$ 3 Million (Three Million United States Dollars only), of which, initially the Company will invest US$ 1 Million (One Million United States Dollars only) for a stake of 51% (Fifty One Percent) as capital contribution and balance will be invested by the Company as and when the funds are required by the subsidiary Company. The balance stake of 49% (Forty Nine Percent) will be held by PT. Mitra Medis Exim (MME), that belongs to Mitra Jaya Group which is a 40 year old multi-diversified group, as the co-promoter of the proposed subsidiary Company. MME is in the business of distribution for active pharmaceutical ingredients and excipients for the end users in Indonesia. The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid acquisition is enclosed as Annexure - I (As Per BSE Announcement Dated on 20.04.2023)
31-Jan-2023	09-Feb-2023	Quarterly Results	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve the unaudited financial results for the quarter ended 31st December 2022 and to consider the third interim dividend if any Board approved:- 1) Declared Third Interim Dividend of Rs.1.25 {one rupee twenty-five paise only i.e., 62.50%) each per equity share of Rs.2/- {Rupees two only) each for the financial year 2022-23. The date for taking on record of its shareholders eligible for the purpose of payment of 3rd' interim dividend i.e., record date is fixed as Tuesday, the 21' day of February, 2023. The payment of said interim dividend will be from l'' March, 2023. 2) The Board of Directors have approved to make the investment for an amount not exceeding Rs.13 Crores (6.68% of the capital on a fully diluted basis) in M/s. Redcliffe Hygiene Private Limited. (As Per BSE Bulletin Dated on 09.02.2023)
31-Oct-2022	10-Nov-2022	Quarterly Results	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2022 inter alia to consider and approve the Unaudited Financial Results for the quarter and half year ended 30th September 2022 and to consider 2nd interim dividend if any for the financial year 2022-23. Outcome of the Board Meeting held on 10-Nov-2022 to consider the unaudited financial Results for the quarter and half year ended 30th September 2022 and declared 2nd Interim Dividend of Rs.0.75 (i.e., 37.50%) per Equity shares of Rs.2/- each Record Date for payment of 2nd Interim Dividend is 22nd November 2022 (As Per BSE Announcement Dated on 10.11.2022)
02-Sep-2022	02-Sep-2022	Others	Outcome of the Board Meeting held on 2nd September, 2022
01-Aug-2022	09-Aug-2022	Quarterly Results	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 inter alia to consider and approve consideration of unaudited Financial Results and Interim Dividend for FY 2022-23 if any Unaudited Financial Results for the Quarter ended 30th June, 2022 and Interim Dividend of Rs.3.50 per equity share of Rs.2/- each On the basis of the recommendations of Nomination & Remuneration Committee in its meeting held today, the Board of Directors have co-opted Dr. Pavan Ganapati Bhat (DIN: 09691260) as an Additional Director and appointed him as an Executive Director i.e., Director & Executive Vice President (Technical Operations) of the Company for a period of 2 (two) years w.e.f. 9th August, 2022 subject to approval of the members of the Company at the ensuing Annual General Meeting. Brief Profile of Dr. Pavan Ganapati Bhat, in terms of the SEBI Listing Regulations, is annexed herewith as Annexure - 1. Unaudited Financial Results for the Quarter ended 30th June, 2022 and Interim Dividend of Rs.3.50 per equity share of Rs.2/- each On the basis of the recommendations of Nomination & Remuneration Committee in its meeting held today, the Board of Directors have co-opted Dr. Pavan Ganapati Bhat (DIN: 09691260) as an Additional Director and appointed him as an Executive Director i.e., Director & Executive Vice President (Technical Operations) of the Company for a period of 2 (two) years w.e.f. 9th August, 2022 subject to approval of the members of the Company at the ensuing Annual General Meeting. Brief Profile of Dr. Pavan Ganapati Bhat, in terms of the SEBI Listing Regulations, is annexed herewith as Annexure - 1. (As Per BSE Announcement Dated 09.08.2022)
20-May-2022	30-May-2022	Accounts	NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Approval of the Audited Financial Results for the quarter and year ended 31st March 2022; Financial Results for the quarter and year ended 31st March, 2022 (As Per BSE Announcement Dated on 30/05/2022)
07-Feb-2022	14-Feb-2022	Quarterly Results	Third Interim Dividend & Quarterly Results Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2022, inter alia, has declared 3rd interim dividend of Rs. 2/- each per Equity share of Rs. 2/- each for the financial year 2021-22 (which is 100% on the nominal value of the equity share). The payment of said interim dividend will start from March 04, 2022. (As Per BSE Announcement Dated on 14.02.2022)

1 2

LOGIN HERE

Natco Pharma Ltd

Board Meeting